Grufity logoGrufity logo
ScreenerStocksFundsSectorsWatchlists
OCUL

Ocular Therapeutix Inc

OCUL

3.76USD+0.13 (+3.58%)Delayed as of 07 Dec 2023, 03:12 pm
Watchlist

Market Summary

USD3.76+0.13
Delayedas of 07 Dec 2023, 03:12 pm
3.58%

OCUL Stock Price

View Fullscreen

OCUL RSI Chart

OCUL Valuation

Market Cap

288.3M

Price/Earnings (Trailing)

-4.3

Price/Sales (Trailing)

4.99

Price/Free Cashflow

-3.98

OCUL Price/Sales (Trailing)

OCUL Profitability

Return on Equity

-914.57%

Return on Assets

-69.08%

Free Cashflow Yield

-25.16%

OCUL Fundamentals

OCUL Revenue

Revenue (TTM)

57.7M

Revenue Y/Y

26.04%

Revenue Q/Q

-0.69%

OCUL Earnings

Earnings (TTM)

-67.1M

Earnings Y/Y

97.87%

Earnings Q/Q

97.51%

Price Action

52 Week Range

2.577.96
(Low)(High)

Last 7 days

41.8%

Last 30 days

31.5%

Last 90 days

-5.2%

Trailing 12 Months

25.2%

How does OCUL drawdown profile look like?

OCUL Financial Health

Current Ratio

3.61

OCUL Investor Care

Shares Dilution (1Y)

3.12%

Diluted EPS (TTM)

-1.12

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202351.7M54.6M57.7M0
202249.4M49.9M49.7M51.5M
202122.1M32.3M38.6M43.5M
20206.3M7.3M12.3M17.4M
20192.1M2.1M2.5M4.2M
20181.8M2.0M2.0M2.0M
20171.9M1.9M1.9M1.9M
20161.8M1.8M1.8M1.9M
20151.2M1.5M1.8M1.8M
2014000772.0K
20130000
201200010.0K

Latest Insider Trading transactions for OCUL

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Aug 30, 2023
mattessich antony c.
bought
24,765
3.81
6,500
president and ceo
Jul 10, 2023
graves adrienne l
acquired
-
-
24,000
-
Jul 07, 2023
ozden rabia gurses
sold
-4,101
4.93
-832
chief medical officer
Jun 14, 2023
hong seung suh
acquired
-
-
12,000
-
Jun 14, 2023
williams leslie j.
acquired
-
-
12,000
-
Jun 14, 2023
heier jeffrey s.
acquired
-
-
12,000
-
Jun 14, 2023
lindstrom richard l md
acquired
-
-
12,000
-
Jun 14, 2023
warden charles m
acquired
-
-
12,000
-
Jun 14, 2023
raines merilee
acquired
-
-
12,000
-
Feb 06, 2023
mattessich antony c.
sold
-83,396
4.24
-19,669
president and ceo

1–10 of 50

Which funds bought or sold OCUL recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Nov 27, 2023
TRUST CO OF VERMONT
added
25.00
-4,940
15,700
-%
Nov 24, 2023
DEUTSCHE BANK AG\
added
19.99
-41,553
112,431
-%
Nov 22, 2023
Graham Capital Management, L.P.
new
-
299,439
299,439
0.01%
Nov 21, 2023
Walleye Trading LLC
sold off
-100
-232,793
-
-%
Nov 21, 2023
Walleye Capital LLC
sold off
-100
-225,311
-
-%
Nov 16, 2023
Financial Gravity Asset Management, Inc.
sold off
-100
-11.00
-
-%
Nov 15, 2023
Tudor Investment Corp Et Al
reduced
-13.28
-489,466
546,884
-%
Nov 15, 2023
JANE STREET GROUP, LLC
reduced
-76.54
-1,137,960
189,543
-%
Nov 15, 2023
MANUFACTURERS LIFE INSURANCE COMPANY, THE
unchanged
-
-64,109
99,654
-%
Nov 15, 2023
GSA CAPITAL PARTNERS LLP
added
96.36
119,000
733,000
0.06%

1–10 of 47

Latest Funds Activity

Are funds buying OCUL calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own OCUL
No. of Funds

Schedule 13G FIlings of Ocular Therapeutix Inc

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 13, 2023
opaleye management inc.
7.89%
6,075,000
SC 13G/A
Feb 09, 2023
vanguard group inc
5.16%
3,976,853
SC 13G/A
Feb 01, 2023
blackrock inc.
6.4%
4,952,737
SC 13G/A
Feb 03, 2022
blackrock inc.
6.7%
5,122,835
SC 13G/A
Feb 01, 2022
opaleye management inc.
7.80%
5,974,800
SC 13G/A
Feb 12, 2021
opaleye management inc.
8.65%
9
SC 13G/A
Feb 02, 2021
blackrock inc.
7.3%
5,512,264
SC 13G
Jun 09, 2020
blackrock inc.
4.8%
3,006,167
SC 13G/A
May 21, 2020
summer road llc
17.0%
11,387,656
SC 13D/A
Mar 25, 2020
summer road llc
18.9%
11,024,020
SC 13D/A

Recent SEC filings of Ocular Therapeutix Inc

View All Filings
Date Filed Form Type Document
Nov 16, 2023
EFFECT
EFFECT
Nov 07, 2023
S-3
S-3
Nov 07, 2023
8-K
Current Report
Nov 07, 2023
10-Q
Quarterly Report
Oct 04, 2023
8-K
Current Report
Oct 03, 2023
8-K
Current Report
Sep 13, 2023
8-K
Current Report
Sep 05, 2023
4
Insider Trading

Peers (Alternatives to Ocular Therapeutix Inc)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
31.4B
-
4.92% 426363.59%
-3.6K
218.4K
- -102.45%
30.7B
10.7B
11.84% -53.56%
-8.86
2.88
-53.67% -129.46%
22.0B
1.7B
4.71% -20.32%
-43.06
12.74
79.37% 56.87%
17.7B
2.3B
23.54% -7.88%
120.62
7.68
15.05% 75.21%
12.4B
3.6B
1.56% -32.86%
29.22
3.44
8.35% -51.49%
MID-CAP
7.5B
272.9M
38.55% 34.32%
-12.3
27.32
141.38% 4.43%
5.6B
-
16.25% 246.63%
-9.66
48.33
54.84% -12.96%
3.5B
631.9M
-10.80% 43.56%
-23.56
5.55
23.54% 31.53%
3.3B
223.4M
11.07% -7.88%
-16.26
14.69
- -26.24%
2.6B
240.7M
-11.66% -25.68%
-12.44
10.6
-1.03% -16.59%
SMALL-CAP
1.5B
348.4M
7.85% -14.88%
24.07
4.29
81.69% -7.29%
662.5M
1.0B
-19.01% -66.75%
-1.21
0.63
-43.15% 58.48%
100.5M
6.4M
-2.56% -78.77%
-0.61
15.6
-44.11% 50.48%
42.3M
-
410.00% -4.38%
-0.65
-
- -29.23%
26.3M
-
17.86% 4717.52%
-0.55
-
- -13.74%

Ocular Therapeutix Inc News

Latest updates
Yahoo Finance06 Dec 202303:38 pm29 hours ago
Investing.com UK04 Dec 202306:10 pm3 days ago
Defense World03 Dec 202307:04 am4 days ago
Stocks Register28 Nov 202301:05 pm9 days ago
Yahoo Finance17 Nov 202308:00 am20 days ago
Best Stocks08 Nov 202312:05 pm29 days ago
Yahoo Finance08 Nov 202308:00 am29 days ago
Yahoo Finance01 Nov 202307:00 am36 days ago
PR Newswire31 Oct 202307:00 am37 days ago
Forbes24 Oct 202307:00 am44 days ago
Simply Wall St15 Oct 202307:00 am53 days ago
Yahoo Finance07 Oct 202307:00 am2 months ago
Yahoo Finance08 Aug 202307:00 am4 months ago
Yahoo Finance02 Aug 202307:00 am4 months ago

Financials for Ocular Therapeutix Inc

Income Statement (Last 12 Months)
(In Thousands)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Revenue-0.7%15,08115,18613,37414,07611,96512,26613,18712,30912,15311,7187,3427,3495,8761,5692,6092,256829650492504498
Costs and Expenses-4.1%34,29535,75635,92333,43733,50932,18231,02030,35831,68231,94927,57021,69219,88219,45319,22323,65723,97322,24920,15017,78715,314
  S&GA Expenses-16.5%9,31511,15310,83510,53310,18610,1409,0639,1379,5768,3918,0866,8116,5206,1537,1307,1426,7777,2253,3472,2911,067
  R&D Expenses-0.5%15,01915,09414,74713,54313,71913,10013,10012,57812,71913,85910,9277,6246,9518,0216,09810,12510,2359,41411,31710,2589,685
Interest Expenses72.1%3,4261,9911,7681,8471,7971,6961,6831,6801,6581,6551,6791,7261,7151,6941,6331,8051,6511,6271,018374424
Net Income97.5%-516-20,682-30,318-15,542-24,188-18,766-12,542-3,8502,657-8,4813,121-85,612-11,944-36,568-21,512-26,017-18,778-24,453-17,124-17,399-15,010
Net Income Margin----1.72*-1.38*-1.19*-0.65*-0.45*-0.15*-2.29*-3.19*-5.92*-8.94*-7.80*-14.16*-14.31*-20.43*-----
Free Cashflow----23,352-19,108-13,963-11,371-18,876-15,784-13,258-20,185-17,517-6,499-13,872-14,921-19,103-20,068-----
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Assets32.5%16212312914915917318820521823124326298.0010773.0079.0089.0090.0010173.0070.00
  Current Assets40.3%14110110713014616017519120421722824682.0090.0055.0060.0070.0065.0079.0056.0058.00
    Cash Equivalents68.6%11267.0079.0010212113514516617919220922871.0084.0048.0056.0065.0062.0076.0061.0057.00
  Inventory2.4%2.002.002.002.002.002.001.001.001.001.001.001.001.001.001.001.001.001.000.000.000.00
  Net PPE-2.6%12.0013.0012.0010.007.007.007.007.007.007.008.008.008.009.009.0010.0010.0011.0011.0010.0010.00
Liabilities29.3%15511911911411210710811713015016018610210284.0082.0077.0081.0076.0037.0025.00
  Current Liabilities8.4%35.0032.0030.0031.0029.0026.0024.0026.0025.0022.0027.0027.0023.0014.0011.0012.0011.0010.009.009.0013.00
Shareholder's Equity154.4%8.003.0010.0035.0046.0066.0080.0088.0087.0080.0083.0076.00-5.00--11.008.0026.0036.0046.00
  Retained Earnings-0.1%-668-667-647-616-601-577-558-545-541-544-536-539-453-441-405-383-357-338-314-297-279
  Additional Paid-In Capital0.8%676671657652648643638634629625620615450447394380369347340333325
Shares Outstanding0.2%79.0079.0078.0077.0077.0077.0077.0077.0077.0076.0076.0076.0063.0057.0052.0050.0047.0043.0042.0042.0039.00
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Cashflow From Operations61.5%-7,732-20,075-19,973-16,958-13,169-10,876-18,600-15,153-12,982-20,056-17,359-6,246-13,658-14,796-18,854-19,467-19,544-19,181-19,386-13,648-10,873
  Share Based Compensation2.2%4,5124,4134,5724,2344,2404,2814,2093,8413,7584,2923,0862,1041,9361,8261,6651,9533,1691,6951,9421,9491,873
Cashflow From Investing87.0%-259-1,990-3,379-2,150-794-495-276-631-276-129-158-253-214-125-249-601-419-493-725-479-473
Cashflow From Financing438.5%51,9359,64578.004583744931296676792,667-1,162163,91322051,06312,8189,09118,6125,33842,30016,32811,373

OCUL Income Statement

2023-09-30
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Revenue:    
Total revenue, net$ 15,081$ 11,965$ 43,642$ 37,419
Costs and operating expenses:    
Cost, Product and Service [Extensible List]Product revenue, netProduct revenue, netProduct revenue, netProduct revenue, net
Cost of product revenue$ 1,377$ 1,073$ 3,895$ 3,528
Research and development15,01913,71944,86039,919
Selling and marketing9,31510,18631,30429,390
General and administrative8,5848,53125,91523,875
Total costs and operating expenses34,29533,509105,97496,712
Loss from operations(19,214)(21,544)(62,332)(59,293)
Other income (expense):    
Interest income1,2122852,524375
Interest expense(3,426)(1,797)(7,187)(5,175)
Change in fair value of derivative liabilities6,722(1,133)1,2908,598
Gains and losses on extinguishment of debt, net14,190 14,190 
Other income (expense), net 1(1)(1)
Total other income (expense), net18,698(2,644)10,8163,797
Net loss$ (516)$ (24,188)$ (51,516)$ (55,496)
Net loss per share, basic$ (0.01)$ (0.31)$ (0.66)$ (0.72)
Weighted average common shares outstanding, basic79,373,27276,975,83978,276,34176,829,434
Net loss per share, diluted$ (0.25)$ (0.31)$ (0.77)$ (0.73)
Weighted average common shares outstanding, diluted85,142,50476,975,83984,045,57382,598,666
Product revenue, net    
Revenue:    
Total revenue, net$ 14,950$ 11,913$ 43,193$ 36,555
Collaboration revenue    
Revenue:    
Total revenue, net$ 131$ 52$ 449$ 864

OCUL Balance Sheet

2023-09-30
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 110,550$ 102,300
Accounts receivable, net23,58921,325
Inventory2,2571,974
Prepaid expenses and other current assets4,8624,028
Total current assets141,258129,627
Property and equipment, net12,4949,856
Restricted cash1,7641,764
Operating lease assets6,8688,042
Total assets162,384149,289
Current liabilities:  
Accounts payable3,9845,123
Accrued expenses and other current liabilities28,88724,097
Deferred revenue317576
Operating lease liabilities1,8781,599
Total current liabilities35,06631,395
Other liabilities:  
Operating lease liabilities, net of current portion7,2518,678
Derivative liabilities24,0226,351
Deferred revenue, net of current portion14,19713,387
Notes payable, net65,12425,257
Other non-current liabilities10693
Convertible Notes, net8,76528,749
Total liabilities154,531113,910
Commitments and contingencies (Note 14)
Stockholders' equity:  
Preferred stock, $0.0001 par value; 5,000,000 shares authorized and no shares issued or outstanding at September 30, 2023 and December 31, 2022, respectively
Common stock, $0.0001 par value; 200,000,000 shares authorized and 79,412,114 and 77,201,819 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively88
Additional paid-in capital676,203652,213
Accumulated deficit(668,358)(616,842)
Total stockholders' equity7,85335,379
Total liabilities and stockholders' equity$ 162,384$ 149,289
OCUL
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cataract surgery; and DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing OTX-TKI, an axitinib intravitreal implant that is in phase 1 clinical trials for the treatment of wet age-related macular degeneration and other retinal diseases; OTX-TIC, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. Ocular Therapeutix, Inc. has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the Company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC, as well as a discovery collaboration with Mosaic Biosciences to identify new targets and therapeutic agents for the treatment of dry age-related macular degeneration (dMAD). The company was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
 CEO
 WEBSITEwww.ocutx.com
 EMPLOYEES274

Ocular Therapeutix Inc Frequently Asked Questions


What is the ticker symbol for Ocular Therapeutix Inc? What does OCUL stand for in stocks?

OCUL is the stock ticker symbol of Ocular Therapeutix Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Ocular Therapeutix Inc (OCUL)?

As of Wed Dec 06 2023, market cap of Ocular Therapeutix Inc is 288.27 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of OCUL stock?

You can check OCUL's fair value in chart. The fair value of Ocular Therapeutix Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Ocular Therapeutix Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for OCUL so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Ocular Therapeutix Inc a good stock to buy?

The fair value guage provides a quick view whether OCUL is over valued or under valued. Whether Ocular Therapeutix Inc is cheap or expensive depends on the assumptions which impact Ocular Therapeutix Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for OCUL.

What is Ocular Therapeutix Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Dec 06 2023, OCUL's PE ratio (Price to Earnings) is -4.3 and Price to Sales (PS) ratio is 4.99. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. OCUL PE ratio will change depending on the future growth rate expectations of investors.